BioSight
Companies
Dianthus Therapeutics, Inc. /DE/ logo

DNTH

NASDAQNEW YORK, NY
Dianthus Therapeutics, Inc. /DE/

Dianthus Therapeutics is a clinical-stage biotech company developing claseprubart and DNTH212 as product candidates, though the specific therapeutic areas and drug modalities are not detailed in this excerpt. The company is focused on advancing these candidates through preclinical and clinical drug development activities with anticipated timelines and regulatory designations.

Price history not yet available for DNTH.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar